Cerebral ischemia-induced inflammatory cascade reaction may aggravate nerve tissue damage and destroy blood-braln barrier, and angiogenesis after ischemia can improve nerve function. Inhibiting inflammatory response after stroke, promoting angiogenesis and protecting blood-braln may reduce nerve tissue damage and promote recovery of neurological function. Monocyte chemotactic protein 1-induced protein inhibits inflammatory signaling pathways through degradating proinflammatory cytokine mRNA. Its unique biological characteristics also suggest that it has the potential protective effect in cerebral ischemia. This article focuses on the roles of monocyte chemotactic protein 1-induced protein in cerebral ischemia.

Objective To investigate the cause of postoperative colorectal cancer anastomotic fistula,the treatment and prevention measures.Methods 2007 -2014,The department of General surgery in Qingdao Municipal hospitals for abdominal colorectal cancer resection(Dixon surgery)were 208 cases,including 13 cases of anastomotic leakage occurred.Retrospective summarized the cause,treatment and preventive measures of abdominal colorectal cancer anastomotic fistula.Results All of 13 patients were discharged,and had no adhesions obstruction,anastomotic stricture,pelvic abscess and other symptoms following -up 6 months after discharge.Conclusion Grasping preopera-tive risk factors of abdominal colorectal cancer for anastomotic fistula,actively preoperative preparation,and master of fine anatomical and surgical point are the main points of the prevention of anastomotic leakage.

Objective To quantify the correlations between Elekta XVI cone beam CT dose and various scanning protocols,providing mathematical models to assess the protocol-dependency of imaging dose during imnage guided radiotherapy.Methods Based on standard protocols and various combinations of kVp and mA on an XVI mounted on an Elekta Versa HD accelerator,the air KERMA was measured at various positions in a standard PTW CTDI body phantom using calibrated PTW 30009 kV chamber and UNIDOS webline electrometer.Weighted CT dose index (CTDIw) was computed thereafter.SigmaPlot 10.0 was used to fit the measurements against mA and/or kVp yielding empirical functions.Results Under standard protocols,the CTDIw of Varian OBI was only 11.23％ (chest) and 9.15％ (pelvis) of Elekta XVI.Using the default and other 4 investigated kVp values,the central and peripheral KERMA were both proportional to mA,and vet the slope value a varied dramatically from 0.479 to 6.679.Major affecting factors included kVp settings,measurement locations,and dosimetric mnetrics,etc.None linear regressions were used to fit kVp against KERMA at various locations and CTDIw (R2 ＞ 0.997).The differences between all coefficients were statistically significant (P ＜ 0.05).The impact of changing both mA and kVp on the dose to phantom center can be described as mGy =(5.917-0.197 ×kVp+0.002 × kVp2-5.063 × 10-6 × kVp3) × mA.Conclusions Imaging dose of Elekta XVI is strongly dependent on scanning paraneters.The proposed mathematical models can be used as efficient and robust indicators of such dependency.

With the continuous improvement of techniques,mini-invasive surgeries have reached a new peak. There is another great revolution about surgery for colorectal cancer from open surgery to laparoscopic surgery and single-incision laparoscopic surgery (SILS) and natural orifice specimen extraction surgery (NOSES) and robot-assisted laparoscopic surgery. NOSES for colorectal cancer has the advantages of mild pain, quick recovery and small surgical scar, however, it is still in infancy. There is no unified standard in terms of naming,indications and contraindications,aseptic principle and no-tumor principle,and technology platform, and thus further clinical data support is needed.

OBJECTIVETo evaluate the quality and clinical applicability of pyrosequencing assay kit for detecting hepatitis B virus resistance (HBV DRT).

METHODSSerial dilutions of the International Standard for HBV DNA were used to test the detection limit of the PCR for HBV DRT. Plasmids containing the either a wild-type (WT) copy or one of 10 mutant (MT) copies of the HBV RT gene were used to prepare a series of samples with various mutation ratios. To construct the linear relationship between the true mutation rate and the detected mutation rate, each sample was repeated at least 10 times. A total of 102 clinical samples were analyzed by Sanger sequencing and retested by the PCR for HBV DRT to determine the concordance of these two methods.

RESULTSThe lower detection limit of the PCR for HBV DRT was 50 IU/ml. Except for the RT236 MT, the correlation between the true mutation rate and the detected mutation rate for the other nine resistance-related mutation sites were excellent, with R² more than 0.98 (P less than 0.001). Among the 102 clinical samples, four were not amplified successfully by PCR. The results were significantly different between the PCR for HBV DRT method and the Sanger sequencing method (x² = 71.2, P less than 0.001), and concordance was observed for 897/969 (92.6%) amino acid positions in 98 samples. Concordant results were achieved in 46/98 (46.9%) samples at all 10 mutation sites. For detection of a single mutation site, concordance rates ranged from 71.5% to 100% at the 10 mutation sites, respectively. Analysis of discordant samples showed that in 87.5% (63/72), Sanger sequencing detected WT and the PCR for HBV DRT detected WT/MT. In 5.6% (4/72) of samples, Sanger sequencing detected WT/MT and the PCR for HBV DRT detected WT. In the remaining 6.9% (5/72) of samples, Sanger sequencing detected WT but PCR for HBV DRT detected MT.

CONCLUSIONThe PCR for HBV DRT showed high sensitivity and accuracy in detecting antiviral drug-resistant mutations. The method is superior to Sanger sequencing for detecting minor mutations and can be used for early detection of a resistance mutation.

Antiviral Agents ; Base Sequence ; Drug Resistance, Viral ; Hepatitis B virus ; Humans ; Mutation ; Plasmids ; Polymerase Chain Reaction ; Sequence Analysis, DNA

OBJECTIVE To systematically review the background of bioequivalence assessment of nasal sprays and nasal aerosols and the guiding considerations for the bioequivalence assessment of these complex drug-device combination products by regulatory authorities in the United States, the European Union(EU) and China. METHODS This article provided detailed explanations on the innovative weight of evidence assessment approach adopted by the US Food and Drug Administration(FDA), and the statistical rationale, methods and considerations for the bioequivalence assessment of nasal sprays and nasal aerosols. Using the calculation methods described in the draft guidance for budesonide inhalation suspension and the draft guidance for fluticasone nasal spray propionate issued by FDA, the statistical parameters of two-sided and one-sided population bioequivalence calculation were realized through R language programming, and pseudo-code for the population bioequivalence (PBE) calculation programs was provided. This article also presented a comprehensive review of published guidelines and summaries review principles of the EU and China for nasal sprays and nasal aerosols equivalence assessment. RESULTS & CONCLUSION Nasal sprays/nasal aerosols is the focus of innovative and generic drug development in recent years. This paper provided valuable considerations references for the research and development, quality control and bioequivalence evaluation of generic preparations of nasal sprays/nasal aerosols.